Tyrosine Kinase Inhibitors for Acute Respiratory Failure Because of Non-small-Cell Lung Cancer Involvement in the ICU

Methods We performed a national multicenter retrospective case series with the participation of the Groupe de Recherche en Reanimation Respiratoire en Onco-Hematologie. Patients with NSCLC who had been admitted to the ICU for acute respiratory failure due to NSCLC involvement between 2009 and 2019 were included in the study if a TKI was initiated during the ICU stay. Cases were identified with the use of hospital-pharmacies records. We collected demographic and clinical data in charts. All charts were reviewed to confirm NSCLC accountability in the acute respiratory failure. Vital status was assessed at the time of study completion (August 2019). The primary outcome was overall survival 90 days after ICU admission, which was estimated by the Kaplan-Meier method. Exploratory univariate analysis was performed to seek potential factors of ICU survival. The ethics committee of Avicenne Hospital approved the study (CLEA2018-66).

Automated summary

This study retrospectively investigated the use of TKI in ICU for NSCLC patients and explored the potential factors associated with ICU survival.